LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Search

Dr Reddy's Laboratories Ltd-ADR

Fechado

SetorSaúde

13.24 1.46

Visão Geral

Variação de preço das ações

24h

Atual

Mín

13.02

Máximo

13.33

Indicadores-chave

By Trading Economics

Rendimento

-9.7B

2.2B

Vendas

-11B

76B

P/E

Médio do Setor

24.556

49.888

Rendimento de Dividendos

0.63

Margem de lucro

2.928

Funcionários

27,527

EBITDA

-13B

6.1B

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.63%

2.38%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

68M

11B

Abertura anterior

11.78

Fecho anterior

13.24

Sentimento de Notícias

By Acuity

50%

50%

155 / 344 Ranking em Healthcare

Dr Reddy's Laboratories Ltd-ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de out. de 2025, 14:47 UTC

Grandes Movimentos do Mercado

Esperion Therapeutics Shares Rise After Blocking Generic Version of Cholesterol Drug

12 de mai. de 2026, 12:16 UTC

Ganhos

Dr. Reddy's Co-Chairman: Branded Businesses, Currency Tailwinds Partially Mitigated Impact >500124.BY

12 de mai. de 2026, 12:16 UTC

Ganhos

Dr. Reddy's Co-Chairman: FY Performance Reflects Impact of Lower Lenalidomide Sales, Several One-Offs >500124.BY

12 de mai. de 2026, 12:08 UTC

Ganhos

Dr. Reddy's Laboratories Board Recommends Final Dividend of INR8/Shr >500124.BY

12 de mai. de 2026, 12:06 UTC

Ganhos

Dr. Reddy's Laboratories 4Q EPS INR2.64 >500124.BY

12 de mai. de 2026, 12:02 UTC

Ganhos

Dr. Reddy's Laboratories 4Q Net INR2.2B Vs. Net INR15.9B >500124.BY

12 de mai. de 2026, 12:01 UTC

Ganhos

Dr. Reddy's Laboratories 4Q Rev INR75.16B Vs. INR85.06B >500124.BY

23 de jul. de 2025, 17:49 UTC

Ganhos

Dr. Reddy's Labs 1Q Global Generics Revenue $75.62B >RDY

23 de jul. de 2025, 17:48 UTC

Ganhos

Dr. Reddy's Labs 1Q EPS $17.02 >RDY

23 de jul. de 2025, 17:48 UTC

Ganhos

Dr Reddy's Labs 1Q Rev $85.45B >RDY

Comparação entre Pares

Variação de preço

Dr Reddy's Laboratories Ltd-ADR Previsão

Consenso de Avaliação

By TipRanks

Vender

1 ratings

0

Comprar

0

Manter

1

Vender

Sentimento

By Acuity

155 / 344 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Dr Reddy's Laboratories Ltd-ADR

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
help-icon Live chat